Unlocking the Next
Chapter of Kidney Care
Meet the Expert Series: Video On Demand-Prof. Michel Jadoul
What are your thoughts on the results of the primary outcome of the composite of kidney disease progression and cardiovascular death of Empagliflozin based on the EMPA-KIDNEY trial?
Related Videos
1:53
EK22||What are the current guidelines recommendation on the use of SGLT-2 inhibitors in T2D and CKD?
2:10
EK22||Is there benefit in eGFR slope decline of Empagliflozin based on EMPOWER Trials from ERO, EMPEROR studies, and EMPA KIDNEY?
1:50
EK22||What is the role of early diagnosis and treatment prompt initiation of therapy including SGLT-2 Inhibitors in CKD Progression?
1:49
EK22||What is the current limitation of RAAS inhibitor? and what is the additional benefit of using SGLT-2 inhibitors in CKD?
Document ID: SC-ASK-00216